Slow infusion of platelets: A possible alternative in the management of refractory thrombocytopenic patients
Year: 2005
Type: article
Abstract: To the Editor: Imatinib mesylate has tremendously changed the clinical course of chronic myeloid leukemia (CML).Higashi and co-workers reported two CML patients who had imatinib-sensitive blast crisis immediately after discontinuation of the drug due to neutropenia in a recent issue of the this journal [1].Herein we report two CML cases that developed extramedullary collection of myeloblasts during the imatinib treatment.
Source: American Journal of Hematology
DOI: 10.1002/ajh.20290
Authors: Aida Narvios, Virgil Reddy, Fernando Martinez, Benjamin Lichtiger
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Biochemistry (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2124234359